CHARACTERISTICS OF PATIENTS WITH PLEURAL MESOTHELIOMA IN THE RUSSIAN FEDERATION
Author(s)
Gorbounova VA1, Bychkov MB1, Vladimirova LY2, Levchenko EV3, Karpenko TD1, Mamontov OY3, Burmistrov V4, Novick D5, Rajan N6, Sholokhova E4, Solovyenko Y4, Tjulandin SA1
1N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, 2Rostov Scientific Research Oncological Institute, Rostov-on-Don, Russia, 3N.N. Petrov Research Oncology Institute, Saint-Petersburg, Russia, 4Eli Lilly Vostok S.A., Moscow, Russia, 5Eli Lilly Holdings Limited, Windlesham, UK, 6Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia
OBJECTIVES Malignant pleural mesothelioma (MPM) is a rare tumour with a poor survival and prognosis. In Russia, the epidemiology of this disease has not been well studied
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN20
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology